It is essential for healthcare and pharmaceutical companies to be aware of both critical and non-critical risks when conducting quality clinical trials.
Kenji Yasukawa is stepping down as chief executive of Japanese pharma group Astellas, to be succeeded by Naoki Okamura – currently chief strategy officer – on 1st April.
The PM Society’s ‘Is Pharma Marketing built on Straw, Sticks, or Bricks?’ interactive information afternoon, held at The Royal Society of Medicine in London late last year, set out to bring